Trials / Completed
CompletedNCT04468347
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
18F-AV-1451 PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
Detailed description
The Australian Imaging Biomarkers and Lifestyle Study (AIBL) is a multicenter multidisciplinary study of Alzheimer's disease and aging funded by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Flagship Initiative, involving research centers in both Victoria and Western Australia. The goal of the A08 protocol was to further investigate the positron emission tomography (PET) imaging results with flortaucipir in patients across the AD spectrum from individuals with subjective memory complaints (SMC) to those with dementia, based on recruitment into the parent AIBL study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | IV injection, 240 megabecquerel (MBq) (6.5 mCi) |
| PROCEDURE | Brain PET scan | positron emission tomography (PET) scan of the brain |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-01
- First posted
- 2020-07-13
- Last updated
- 2020-09-25
- Results posted
- 2020-09-25
Source: ClinicalTrials.gov record NCT04468347. Inclusion in this directory is not an endorsement.